Shorted
Bcal Diagnostics logo
BDX
Pharmaceuticals, Biotechnology & Life Sciences

Bcal Diagnostics

Short interest
0.00%
−0.01 pp 30d
as of 6 June 2025
Reported shorts
304
Shares on issue
365.968M

Bcal Diagnostics (BDX) company profile

Profile, insiders and operations

Company

AI-generated research profile of Bcal Diagnostics

biotechnology
diagnostics
breast cancer
blood test
ASX

BCAL Diagnostics Limited is an Australian biotechnology company focused on developing a non-invasive blood test for breast cancer detection. They aim to complement existing imaging technologies and improve screening outcomes. BCAL has a NATA-accredited commercial laboratory and has partnered with ClearNote Health Inc. to expand its diagnostic portfolio.

Director trades

20 trades recorded

DateDirectorTypeSharesPriceValue
2026-03-20Unknown Director
buy
---
2026-03-19Jayne Shaw
buy
225,000$0.097$21,835
2026-03-19Unknown Director
buy
---
2026-03-18Jayne Shaw
buy
85,000$0.100$8,477
2026-03-17Unknown Director
buy
---
2026-03-16Jayne Shaw
buy
300,000$0.098$29,251
2026-02-20Jayne Shaw
buy
192,000$0.123$23,615
2026-02-20Unknown Director
buy
---
2025-11-07Unknown Director
buy
---
2025-11-03Jayne Shaw
buy
96,722$0.095$9,189
2025-09-08Unknown Director
buy
---
2025-09-02Jayne Shaw
buy
306,697$0.065$19,885
2024-12-19Unknown Director
buy
---
2024-12-18Jayne Shaw
buy
6,000,000--
2024-11-12Unknown Director
buy
---
2024-11-06Jayne Shaw
buy
480,748$0.105$50,478
2024-09-17Unknown Director
buy
---
2024-09-13Jayne Shaw
buy
125,000$0.115$14,375
2024-09-05Unknown Director
buy
---
2024-09-04David Darling
buy
35,880$0.125$4,485

BDX intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required